While KRAS mutations themselves have been associated as prognostic markers, there is considerable and significant heterogeneity in the activation states of the downstream MAPK/ERK pathway, the molecular landscape, response to therapy, and clinical outcome across pancreatic cancers [6–9]. Here, KRAS is linked to pancreatic neoplasm.